Skip to main content

Table 2 Demographic data of HER2+ patients with preserved EF versus decreased EF following TRA exposure

From: Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study

  All Patients Patients with Preserved EF Patients with Decreased EF OR 95% CI p value
Total Number, n (%) 127 114 (89.0) 13 (11.3)
Age (years, mean ± SD) 57 ± 11 57 ± 11 55 ± 10 0.72
BMI (kg/m2, mean ± SD) 32 ± 8 32 ± 12 32 ± 8 1.0
Ethnicity, n (%)
 Black 64 (50) 57 (50.4) 7 (50) 1.0 0.3–2.8 1.0
 White 59 (46) 52 (45.1) 7 (50) 1.19 0.4–3.3 0.75
 Hispanic 5 (4) 5 (4.4)
Breast Cancer Hormonal Status, n (%)
 ER−/PR- 55 (43) 51 (44) 4 (28) 0.49 0.15–1.66 0.25
 ER−/PR+ 1 (0.8) 1 (0.8)
 ER+/PR- 25 (19) 23 (20) 2 (14) 0.66 0.14–3.15 0.60
 ER+/PR+ 47 (37) 39 (34) 8 (57) 2.56 0.83–7.91 0.10
AJCC Breast Cancer Stage, n (%)
 I 34 (27) 32 (28) 2 (14) 0.43 0.09–2.01 0.28
 II 59 (45) 51 (45) 8 (57) 1.64 0.53–5.05 0.38
 III 18 (12) 17 (13) 1 (7) 0.44 0.05–3.57 0.44
 IV 17 (13) 14 (12) 3 (21) 1.94 0.48–7.85 0.34
Chemotherapy Regimen, n (%)
 AC ➔ TRA 40 (31) 34 (30) 6 (43) 1.76 0.5–5.5 0.32
 Non-AC ➔ TRA 88 (68) 80 (70) 8 (57) 0.56 0.2–1.7 0.32
Ejection Fraction (%)
 Baseline (mean ± SD) 64 ± 7 64 ± 7 62 ± 9 0.16
 Median Decrease       
 3 months 1 ± 7 10 ± 0
 6 months 3 ± 6 10 ± 10
 9 months 4 ± 11 17 ± 9
Past Medical History, n (%)
 Arrhythmia 6 (5) 4 (4) 2 (15) 4.58 0.76–27.7 0.09
 CAD 8 (6) 6 (5) 2 (15) 3.0 0.54–16.5 0.21
 DM 32 (25) 28 (25) 4 (31) 1.22 0.36–4.22 0.74
 HTN 78 (61) 69 (61) 9 (69) 1.17 0.37–3.73 0.78
Social History, n (%)
 Smoker 46 (36) 38 (33) 8 (57) 2.67 0.86–8.24 0.08
 Alcohol 23 (18) 21 (18) 2 (14) 0.73 0.15–3.55 0.70
Medications, n (%)
 Anti-RAAS 49 47 (32.4) 2 (23) 0.26 0.05–1.22 0.06
 BB 24 20 (17.5) 2 (30.7) 0.85 0.17–4.17 0.84
 CCB 22 20 (17.5) 2 (15.4) 0.85 0.17–4.17 0.84
 Loop diuretic 16 15 (13.1) 1 (7.7) 0.55 0.07–4.50 0.58
 Thiazide diuretic 31 29 (25.4) 2 (15.4) 0.48 0.11–2.54 0.37
 Statin 25 23 (20.2) 2 (15.4) 0.65 0.15–3.47 0.60
  1. Abbreviations: AC anthracycline, BB beta-blocker, CAD coronary artery disease, CCB calcium channel blocker, CKD chronic kidney disease, DM diabetes mellitus, ER estrogen receptor, HLD hyperlipidemia, HTN hypertension, OSA obstructive sleep apnea, PR progesterone receptor, RAAS renin-angiotensin-aldosterone system. p < 0.05 was considered statistically significant